CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ALX148Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug260 Azacitidine Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D011289 Preleukemia NIH 0.71
D009190 Myelodysplastic Syndromes NIH 0.58
D013577 Syndrome NIH 0.11

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002863 Myelodysplasia HPO 0.58

There is one clinical trial.

Clinical Trials


1 A Phase 1/2 Study of ALX148 in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS)

This Phase 1/2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

NCT04417517 Higher Risk Myelodysplastic Syndromes Drug: ALX148 Drug: Azacitidine
MeSH:Preleukemia Myelodysplastic Syndromes Syndrome
HPO:Myelodysplasia

Primary Outcomes

Description: Number of participants with a DLT

Measure: Phase 1: Dose Limiting Toxicities (DLT)

Time: Up to 28 days

Description: Number of participants achieving a response per International Working Group (IWG) criteria

Measure: Phase 2: Objective response rate (ORR)

Time: Approximately 6 months


Related HPO nodes (Using clinical trials)